Table 3 Adverse reactions of favipiravir
From: Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
Reported adverse drug reactions | ||
|---|---|---|
Favipiravir | Comparator drug | |
Chen C, et al. (China) | Antiviral-associated adverse effects among favipiravir group were (n, %): Abnormal LFT, 10 (8.62); Raised serum uric acid, 16 (13.79); Psychiatric symptoms reactions, 5 (4.31); Digestive tract reactions, 16 (13.79) | Among arbidol group (n, %): Abnormal LFT, 12 (10.00); Raised serum uric acid, 3 (2.50); Psychiatric symptoms reactions, 1 (0.83); Digestive tract reactions, 14 (11.67) |
Lou Y, et al. | Respiratory failure occurred in 14 patients. Other adverse events were generally mild or moderate among the three Groups. The most frequent adverse events 2 occurring in the study population were similar among all groups, including elevation of 3 triglyceride (20 events), liver function abnormality (18 events), rash (7 events), and diarrhea (4 events). No abnormal 5 serum creatinine was found in all patients. | |
Ivashchenko AA, et al. (Russian Federation) | Adverse drug reactions were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) | N/A |
Cai Q, et al. | Total numbers of adverse reactions were 4 in favipiravir 5.71% reported diarrhea, respectively. None of reported for vomiting, nausa, and rash. | Total numbers of adverse reactions were 24 in LPV/RTV groups. 11.11% reported diarrhea, respectively. 11.1, 13.33, 8.89% of LPV/RTV group reported vomiting, nausa, and rash, respectively. |
Doi Y, et al. (Japan) | Among 82 patients, total 144 adverse events. The most common was hyperuricemia (84.1%). Of 32 patients who had serum uric acid level determined, 24 had the level normalized to below 7 mg/dL, with the highest being 8.8 mg/dL. Serum triglyceride elevation (11.0%) Serum alanine aminotransferase elevation (8.5%). | N/A |